How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A DecadeInvestors Business Daily • 10/29/26
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 10/26/26
The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement SchemeBusiness Wire • 10/23/26
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBDBusiness Wire • 10/22/26
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/22/26
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026Business Wire • 10/22/26
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 10/21/26
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026Business Wire • 10/19/26
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?The Motley Fool • 10/18/26
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026Business Wire • 10/15/26
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Zacks Investment Research • 10/15/26
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer betsMarket Watch • 10/15/26
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 10/15/26